Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

430

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis
Primary Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Pelabresib
DRUG: Ruxolitinib
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals